[Comment] Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma

Historically, hepatocellular carcinoma was deemed to be inherently drug resistant due to the presence of multidrug resistance genes that increased drug efflux and reduced drug uptake. For decades, multiple trials investigating systemic therapy for advanced hepatocellular carcinoma had failed to show clinical efficacy. In 2008, Llovet and colleagues1 reported that median survival and the time to radiological progression were nearly 3 months longer for patients treated with sorafenib versus placebo.